Skip to main content

Pre-eclampsia: an update.

TitlePre-eclampsia: an update.
Publication TypeJournal Article
Year of Publication2014
Authorsvon Dadelszen, P, Magee, LA
JournalCurr Hypertens Rep
Volume16
Issue8
Pagination454
Date Published2014 Aug
ISSN1534-3111
KeywordsAspirin, Blood Pressure, Female, Humans, Magnesium, Pre-Eclampsia, Pregnancy, Risk
Abstract

Pre-eclampsia remains the second leading direct cause of maternal death, >99 % of which occurs in less developed countries. Over 90 percent of the observed reduction in pre-eclampsia-related maternal deaths in the UK (1952-2008) occurred with antenatal surveillance and timed delivery. In this review, we discuss the pathogenesis, diagnostic criteria, disease prediction models, prevention and management of pre-eclampsia. The Pre-eclampsia Integrated Estimate of RiSk (PIERS) models and markers of angiogenic imbalance identify women at incremental risk for severe pre-eclampsia complications. For women at high risk of developing pre-eclampsia, low doses of aspirin (especially if started <17 weeks) and calcium are evidence-based preventative strategies; heparin is less so. Severe hypertension must be treated and the Control of Hypertension In Pregnancy (CHIPS) Trial (reporting: 2014) will guide non-severe hypertension management. Magnesium sulfate prevents and treats eclampsia; there is insufficient evidence to support alternative regimens. Pre-eclampsia predicts later cardiovascular disease; however, at this time we do not know what to do about it.

DOI10.1007/s11906-014-0454-8
Alternate JournalCurr. Hypertens. Rep.
Citation Key619
PubMed ID24915961
Grant List / / Canadian Institutes of Health Research / Canada